## **REMARKS**

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "Version With Markings to Show Changes Made".

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1

2200 Clarendon Boulevard, Suite 1400

Arlington, VA 22201 Direct Dial: 703-812-5311 Facsimile: 703-243-6410 Email: zelano@mwzb.com

AJZ:jmm

FILED: 3 AUGUST 2001

## VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 4-6, 8-13 and 15-16 have been amended as follows:

- 4. (Amended) Combination according to one of the preceding claims  $\underline{1}$ , whereby the cyclodextrin is a  $\beta$ -cyclodextrin.
- 5. (Amended) Combination according to one of the preceding claims 1, whereby the cyclodextrin and the gestagen

are present with  $\beta$ -cyclodextrin in a complex of 1:n (gestagen : cyclodextrin, n  $\geq$  1), and are present with  $\gamma$ -cyclodextrin in a complex of 1:n (n  $\geq$  1) (gestagen : cyclodextrin).

- 6. (Amended) Combination according to one of the preceding claims 1 as a pharmaceutical agent.
- 8. (Amended) Combination according to claim 6 or 7 for the production of a pharmaceutical agent for treating menopausal symptoms.
- 9. (Amended) Combination according to one of the preceding claims 1 to 5 for birth control.
- 10. (Amended) Pharmaceutical agent or pharmaceutical preparation that contains a combination according to one of the preceding claims 1 with pharmaceutically compatible adjuvants and vehicles.
- 11. (Amended) Pharmaceutical agent or pharmaceutical preparation that contains a combination according to one of the preceding claims 1 for peroral, oral, parenteral, transdermal, pulmonary, nasal, rectal, vaginal or intrauterine use.
- 12. (Amended) Use of a combination according to one of the preceding claims 1 to 9 for the production of a medication for treating premenstrual symptoms, such as headaches, depression, water retention and mastodynia.
- 13. (Amended) Process for birth control with administration of a combination according to one of claims 1 to 9.
- 15. (Amended) Process for complexing a gestagen according to one of claims 1-and 2 and a  $\beta$ -cyclodextrin or  $\gamma$ -cyclodextrin while being triturated as a dry mixture or by precipitation reaction, preferably co-precipitation.

16. (Amended) Process for direct pelletizing of a gestagen complex according to one of claims 1 and 2 with a  $\beta$ -cyclodextrin or  $\gamma$ -cyclodextrin with the addition of pharmaceutically compatible adjuvants.